Product innovations > White / Technical Paper
Fill form to download now!
Please note that any information that you supply is protected by our Privacy Policy.
Access to all documents and request for further information are available to all users at no cost. In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information may be shared with the owners of that document or information.
Biopharmaceutical Drug Developers topic: Detection of protein aggregation by AF4/MALS
|
The formation of aggregates in biopharmaceuticals such as monoclonal antibodies (MAbs), represents a severe problem, which has also been addressed by FDA authorities recently. Particularly their potential to trigger or enhance undesirable immune responses may cause adverse clinical effects or compromise the drug’s safety and efficiency. Wyatt Technology has recently launched the 4th generation AF4/MALS technology, specifically aiming at providing drug developers a truly orthogonal method to SEC. The attached paper gives you more background and technical information on this method.
